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doi:10.1016/j.ejvs.2008.02.004Abstract Objective: A significant proportion of patients with ischemic heart disease have
associated peripheral arterial disease (PAD), but many are asymptomatic and this condition
remains underdiagnosed. We aimed to study the prevalence of PAD in patients with an
acute coronary syndrome (ACS) and to evaluate its influence in hospital clinical outcomes.
Methods: The PAMISCA register is a prospective, multicenter study involving patients 40 years
old with ACS admitted to selected Spanish hospitals. All patients had their ankle-brachial index
(ABI) measured between days 3 and 7 after the ischemic event.
Results: 1410 ACS patients (71.4% male) were included. PAD determined by ABI was documen-
ted in 561 patients (39.8%). Factors independently related to PAD were age (OR: 1.04; 95% CI:
1.03e1.06; p< 0.001), smoking (OR: 1.88; 95% CI: 1.41e2.49; p< 0.0001), diabetes (OR: 1.30;
95% CI: 1.02e1.65; p< 0.05), previous cardiac disease (OR: 1.54; 95% CI: 1.22e1.95; p< 0.001)
and previous cerebrovascular disease (OR: 1.90; 95% CI: 1.28e2.80; p< 0.001). Following thelas Blasco, Cardiology Department, Hospital Universitario San Juan, Ctra. Nacional 332 Alicantee
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190 V. Bertomeu et al.ACS, an ABI 0.90 was associated with increased cardiovascular mortality (OR: 5.45; 95% CI:
1.16e25.59; p< 0.05) and a higher risk of cardiovascular complications.
Conclusion: The prevalence of PAD in patients 40 years presenting with ACS is high and it is
associated with increased cardiovascular risk.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Atherosclerosis is a progressive and diffuse pathological
disorder which can simultaneously affect multiple vascular
beds.1e3 Peripheral arterial disease (PAD) often coexists with
other manifestations of the systemic atherosclerotic process,
including coronary artery disease and cerebrovascular dis-
ease.Clinically, themainsymptomofPAD is intermittentclau-
dication; however the disease is frequently asymptomatic.4
Previous studies have shown that PAD is associated with
a high risk of cardiovascular events and mortality in patients
with or without known coronary artery disease, and in-
dependent of the presence of other cardiovascular risk
factors.4e6 However, PAD, especially sub-clinical disease,
has not been fully analyzed in patients who suffer an acute
coronary event.7,8 The ankle-brachial index (ABI) is a non-
invasive and sensitive method for estimating atherosclerosis
in the lower limbs with values 0.9 indicating the presence
of PAD in patients with or without symptoms. Importantly,
abnormal ABI values have been associated with an increase
in cardiovascular morbidity and mortality.9,10
The objective of the present study is to evaluate the
prevalence of PAD in patients with acute coronary syndrome
(ACS) through determination of the ABI, and to analyse its
influence on the short-term prognosis of these patients.
Materials and Methods
The PAMISCA register (Prevalencia de Afectacio´n de Miem-
bros Inferiores en el paciente con Sı´ndrome Coronario
Agudo), is an observational, prospective, multicenter
study, designed to investigate the prevalence of PAD in pa-
tients admitted to Spanish hospitals with a diagnosis of ACS.
Study population
Between September and December 2005 patients with ACS
consecutively admitted to the Cardiology Departments of
the selected hospitals in Spain were included. From Spanish
ministry of Health records, we compiled a list of >50 bed
non-specialist centres with a Cardiology department and
Intensive Care Unit/Coronary Unit. Using this list we
conducted a random selection and centers were invited
to participate in the study. A total of 94 hospitals accepted
and entered into the study.
The criteria for inclusionwere patients aged40 years and
hospital admission for ACS defined by: (1) typical clinical
symptoms of chest pain; (2) electrocardiographic changes
indicativeofmyocardial ischemia/lesion;and/or (3) elevation
of serum markers of myocardial damage. Exclusion criteria
were age< 40 years, death of the patient in the first 48 hours
after hospital admission, ACS of non-atherothrombotic origin(e.g. embolism due to myxoma, vasospasm due to cocaine,
etc.). Informed consent was obtained from all patients and
the study was carried out following the principles of the
Helsinki Declaration (Edinburgh Amendment, 2000).
Clinical evaluation
Risk factors and cardiovascular history of patients were
collected following a standard questionnaire. The main risk
factors were hypertension (all patients with a history of
hypertension or who were receiving antihypertensive ther-
apy), diabetes (all patients with a history of diabetes
mellitus or who were receiving antidiabetic therapy),
hypercholesterolemia (all patients with a history of high
LDL cholesterol (>160 mg/dl) or who were receiving lipid-
lowering treatment or dietary control), and smoking (all
patients who regularly smoked an average of one or more
cigarettes a day for at least 1 year). Patients who had given
up smoking for 12 months were considered ex-smokers.
Diagnosis of PAD
The presence of PAD was defined by an ABI value 0.9.
Additionally, patients with a history of peripheral vascular
revascularisation and/or ischemic amputation of the leg
were also considered as patients with PAD in the statistical
analysis independent of their ABI values. Calculation of the
ABI of both limbs was determined between the third and
seventh day of the ischemic episode using a pocket Doppler
BIDOP ES-100V3ª and a blood pressure cuff, as previously
described.10 In brief, systolic blood pressure was measured
in both arms and both ankles (posterior tibial artery) with
the patient in the supine position. The ABI of each leg
was calculated by dividing the systolic pressure of the right
and left ankle by the greater systolic pressure of both arms
and the lowest ABI value was selected. Each center re-
ceived identical Doppler equipment and specific training
for measuring ABIs so as to ensure the accuracy and consis-
tency of the measurements.
Hospital complications
The primary outcome variables were, cardiovascular mor-
tality, recurrent myocardial ischemia, acute heart failure,
atrial fibrillation/flutter, ventricular tachycardia/fibrilla-
tion, 2nde3rd degree AV-block, transient ischemic attacks
and stroke.
Statistical analysis
All data collected in the study is described in terms of
central trend, dispersion measurements and relative fre-
quencies. The Student’s T test was used for comparison of
Figure 1 Distribution of ABI values in 1410 patients admitted to hospitals with acute coronary syndrome.
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parison of the categorical variables.
Binary logistic regression models were developed to
determine which variables independently related with the
presence of PAD or with hospital complications. Variables
with significance in the bivariate analysis and those of
known clinical relevance were included in the model. The
statistical program SPSS version 13 was used for the
analysis. A value of p< 0.05 was considered statistically
significant.
Results
Demographic and baseline characteristics of the
study population
1410 patients (71.4% male) of mean age 66 11.9 (range
40e101) years were available for analysis. 84.1% of the pa-
tients had history of hypercholesterolemia, 79.3% were hy-
pertensive, 35% had diabetes, 30.9% were smokers and
28.2% ex-smokers. With regards the acute coronary eventTable 1 Baseline risk factors and cardiovascular history in pati
Baseline risk factors/Demographics PAD (nZ 56
Mean SD age, years 69.2 11.3
Males (%) 386 (69.7)
Hypertension (%) 472 (84.1)
Diabetes mellitus (%) 233 (41.5)
Current smoker (%) 168 (29.9)
Ex-smoker (%) 168 (29.9)
Hypercholesterolemia (%) 481 (85.7)
Family history PCVD (%) 88 (15.7)
History of cardiac disease (%) 284 (50.6)
Previous cerebrovascular disease (%) 75 (13.4)
History of aortic disease (%) 15 (2.7)
PCVDZ premature cardiovascular disease; ns: not significant.it was associated with ST segment elevation in 593 patients
(42.1%). The myocardial area most frequently affected was
the inferior wall in 32.2% of patients, followed by the ante-
rior wall (29.3%), and lateral wall (15.6%) while it was not
possible to specify the location in 22.9%.
Treatment strategy
232 of 593 patients (39.1%) with ST elevation received
thrombolytic therapy. Of the total study population (1410
patients with ACS), percutaneous coronary angioplasty was
performed in 780 patients (55.3%) during their hospital stay.
Drugs administered at discharge included aspirin (86.7%
of patients), clopidogrel (68.2%), oral anticoagulants
(7.4%), statins (81.9%), b-blockers (72.9%) and angioten-
sin-converting-enzyme inhibitors (51.5%).
Prevalence of PAD
PAD was previously known in 100 patients (7.1%) e this
included 26 patients (1.8%) with angioplasty or surgicalents with or without PAD
1) No PAD (nZ 849) p
63.9 11.8 <0.001
614 (72.6) ns
646 (76.1) <0.001
260 (30.6) <0.001
268 (31.6) ns
229 (27) ns
705 (83) ns
138 (16.3) ns
306 (36) <0.001
50 (5.9) <0.001
1 (0.1) <0.001
192 V. Bertomeu et al.revascularisation of lower limbs, and 10 patients (0.7%)
with surgical amputation. Using ABI measurements a de-
finitive diagnosis of PAD was established in 561 patients
(39.8%). The distribution of ABIs is presented in Fig. 1. Of
the 561 patients with PAD, only 184 patients experienced
intermittent claudication (32.8%). The prevalence of PAD
increased with age, from 22.2% in patients from 40e49
years to 57% in those over 80.
Table 1 shows the distribution of cardiovascular risk fac-
tors in individuals with and without PAD. Patients with PAD
were significantly older and they had a higher prevalence of
hypertension and diabetes than those without PAD. Further-
more more PAD patients had a previous history of ischemic
heart disease, cerebrovascular disease and aortic pathology
than those without PAD. In the logistic regression analysis
the factors independently associated with a greater risk of
having PAD were age (OR: 1.04; 95% CI: 1.03e1.06;
p< 0.001), diabetes (OR: 1.30; 95% CI: 1.02e1.65; p< 0.05),
smoking (OR: 1.88; 95% CI: 1.41e2.49; p< 0.0001), history
of cardiac disease (OR: 1.54; 95% CI: 1.22e1.95; p< 0.001)
and previous cerebrovascular disease (OR: 1.90; 95% CI:
1.28e2.80; p< 0.001) (Fig. 2).
Hospital complications
During hospitalization patients with PAD had a worse
prognosis, with a greater incidence of cardiovascular
mortality, atrial fibrillation/flutter, recurrent myocardial
ischemia and heart failure (Table 2). There were 13 deaths
(0.9%), 11 in the PAD group and 2 in the non-PAD group
(pZ 0.001). Cardiovascular mortality increased with more
severe PAD as estimated by lower ABI values: 1% in patients
with ABI values between 0.91e1.4; 2.5% in patients with
ABIs between 0.69e0.41; and 4.5% in patients withFigure 2 Logistic regression analysis of the factors associated w
were: age, sex, hypertension, hypercholesterolemia, diabetes, sm
ease and family history of early cardiovascular disease. PCVDZ prABIs 0.4 (p< 0.005). One patient with an ABI> 1.4 died
(3.4%) (Fig. 3). Patients with symptomatic PAD have higher
rate of complications than asymptomatic PAD patients:
higher cardiovascular mortality (3.8% vs. 1.1%; p< 0.05),
ventricular tachycardia/fibrillation (4.3% vs. 1.3%;
p< 0.05) and heart failure (21.7% vs. 13%; pZ 0.01).
In the multivariate analysis, the presence of PAD was
associated with greater cardiovascular mortality after the
ACS (OR: 5.45; 95% CI: 1.16e25.59; p< 0.05), as well as
a greater risk of hospital complications (Fig. 4).
Discussion
The present study is one of the first registers to analyse the
relationship between PAD (especially sub-clinical PAD) and
ACS, by actively and systematically determining peripheral
vascular function in patients suffering an acute coronary
event. The results of our study show that the prevalence of
PAD in patients with ACS was nearly 40%. This prevalence is
higher than previously communicated. For example, in
a sub-analysis of the GRACE study which included 41,108
patients admitted for an ACS, Froelich et al. reported
a prevalence of 9.7%.8 Likewise, Cotter et al. documented
extra-cardiac vascular impairment in 11.4% of patients, of
whom 6.8% had PAD.7 The presence of PAD is probably
underdiagnosed in both of these studies, given that only
patients with previously diagnosed disease were included,
and no tests were performed to identify patients with
sub-clinical PAD. It is well known that a large proportion
of patients with atherosclerotic disease in the lower limbs
are asymptomatic,11,12 and our results showed likewise,
with only 184 patients (32.8%) with a diagnosis of PAD pre-
viously reporting claudication. The ABI represents a simple,
non-invasive and inexpensive procedure for estimatingith the presence of PAD. The variables evaluated in the model
oking, previous cardiac disease, previous cerebrovascular dis-
emature cardiovascular disease; ns: not significant.
Table 2 Hospital complications in 1410 patients (561 with PAD and 849 without PAD) admitted following an acute coronary
event
Hospital complication PAD (%), (nZ 561) No PAD (%), (nZ 849) p
Cardiovascular mortality 2 % (11) 0.2 % (2) 0.001
Recurrent myocardial ischemia 13.7 % (77) 7.8 % (66) <0.001
Heart failure 15.9 % (89) 8.4 % (71) <0.001
Atrial fibrillation/flutter 9.6 % (54) 4.9 % (42) <0.001
Ventricular tachycardia/fibrillation 2.3 % (13) 2.7 % (23) ns
2nde3rd degree AV-block 2 % (11) 2.7 % (23) ns
Stroke 0.4 % (2) 0.4 % (3) ns
Transient ischemic attack 1.4 % (8) 0.5 % (4) 0.056
nsZ Not significant.
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nosis of PAD increased significantly in our study after deter-
mining the ABI in this population, increasing from 7.1% of
patients with previous clinical diagnosis of PAD to 39.8%.
Recently, the AGATHA study (a Global Atherothrombosis As-
sessment) revealed the presence of an abnormal ABI (0.9)
in 40% of patients with atherothrombosis (coronary, cere-
bral or peripheral disease) and in 31% of patients with sev-
eral cardiovascular risk factors, but without previous
cardiovascular disease.13
There is a close relationship between the prevalence of
PAD and age, both in the general population14 and in patients
with established coronary artery disease,15 as our study con-
firms. Virtually half of the patients over 70 years in our pop-
ulation had PAD, a great majority of them asymptomatic.
The PARTNERS study which involved primary care patients
documented a high prevalence of PAD in those aged over
70 years and in middle-aged patients with a history of diabe-
tes and/or smoking.11 In the context of ACS, patients with
a history of PADwere significantly older. Singh et al. analysed
the influence of PAD in 7696 patients who underwent coro-
nary percutaneous intervention and stent implantation and
found that patients with PAD (nZ 1397) had a higher meanFigure 3 Hospital complications classified according to ABI level
normal ABI values were excluded from the analysis because of percu
zp< 0.001 (ANOVA test).age (71.1 vs. 65 years; p< 0.01), as well as greater preva-
lence of hypertension, diabetes mellitus, hyperlipidemia
and history of smoking.16
Various population studies have revealed that an
ABI 0.9 is highly predictive for cardiovascular morbidity
and mortality, both in the general population and in pa-
tients with known coronary artery disease.5 Few studies
have directly analysed the role of PAD in the prognosis of
patients with ACS.17 The American study GRACE observed
an increase in the combined end-point (death, shock, an-
gina and stroke) in patients with history of PAD compared
to patients without PAD (adjusted OR, 1.17; 95% CI, 1.08e
1.26).8 Our study confirms for the first time the association
between an ABI 0.9 and a greater risk of cardiovascular
mortality after an ACS, as well as a greater incidence of
hospital complications (recurrent myocardial ischemia,
heart failure and atrial fibrillation/flutter). In fact, as ABI
diminishes there was a clinically significant increase in hos-
pital complications and cardiovascular mortality. Recently,
the INVEST study which included hypertensive patients with
associated coronary disease, PAD was identified as a risk
factor for mortality during follow-up.18 In patients undergo-
ing percutaneous coronary intervention, the presence ofin 1405 patients admitted to hospital for ACS (5 patients with
taneous revascularization or leg surgery). *p< 0.01; yp< 0.005;
Figure 4 Multivariate analysis of cardiovascular mortality and hospital complications in patients with PAD.
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diovascular complications and mortality during the hospital
phase and after 1-year’s follow-up.19 A decreased ABI has
been shown to be associated with more severe and diffuse
ischemia, structural heart disease (for example left ventric-
ular hypertrophy) and carotid intima-media thickening in
patients with coronary artery disease.20,21 In the current
study, patients with PAD had a higher prevalence of coro-
nary artery, cerebrovascular and aortic disease. Chang
et al. reported that an ABI< 0.9 identifies a population
with greater complexity and severity of coronary obstruc-
tions, which may be useful when it comes to identifying
high-risk patients.22
The calculation of ABI may be of limited value in some
patients, particularly diabetics, since calcification of the
tibial arteries may cause them to be less compressible,
resulting in unusually high ABI values (>1.40). In our series,
29 patients had high ABI values (>1.4). In these conditions,
the ABI cannot distinguish between patients with or without
arterial occlusion, thus making the ABI unreliable in these
patients. However, an elevated ABI can also be a predictor
for increased cardiovascular risk,15 as confirmed in our
study. In the Strong Heart Study, native Americans with
an ABI> 1.4 or incompressible arteries presented a greater
risk of cardiovascular and all-cause mortality than those
with an ABI between 0.9 and 1.4, pointing to the existence
of a ‘‘U’’ curve between ABI and mortality.6 Recently the
Cardiovascular Health Study confirmed the non-linear asso-
ciation between ABI and mortality, with a poorer prognosis
in those patients with ABI 1.0 and >1.4.23
The main strengths of the PAMISCA study are its pro-
spective design involving a large cohort of ACS patients in
everyday clinical practice, the participation of different
hospital centres randomly selected throughout Spain, and
the fact that ABI was determined for all patients to assess
the level of PAD. This provides for the first time a clear view
of the current relationship between PAD, including those
patients with sub-clinical disease, and ACS.
Limitations of the study relate to the open and un-
controlled nature of the trial design (this is partly mitigated
by the large population of patients included), the exclusionof patients younger than 40 years, and the fact that ABI was
measured between days 3 and 7 after hospital admission
(by which time some patients had already died). These
latter 2 limitations mean that the reported PAD prevalence
data are limited to study population assessed (patients 40
years surviving an ACS), albeit that this represents the
majority of patients.
In conclusion, the prevalence of PAD in patients 40
years presenting with an ACS is high, especially in elderly
patients, smokers, diabetics and those with previous
history of cardiovascular disease. Furthermore, the pres-
ence of PAD (indicated by an ABI 0.9) identifies a popu-
lation at high risk of cardiovascular complications during
the hospital stay following an ACS. Our findings suggest
that the routine determination of ABI in the clinical eval-
uation of patients presenting with an acute coronary
event may help identify patients at higher risk of devel-
oping a secondary cardiovascular event and may assist
us in making decisions for prevention and treatment in
this population.Acknowledgements
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